Work

Lipophilic bisphosphonates plus rapamycin: a deadly combination for KRAS-mutated lung adenocarcinoma.

Year: 2015

Type: article

Abstract: Lung cancer has remained the No. 1 cause of cancer mortality in the world, responsible for more than a million deaths annually. Lung adenocarcinoma is one of the three major subtypes of non-small cell lung cancer (NSCLC), the most common type of lung cancer. About half of the lung adenocarcinomas harbor driver mutations that may serve as therapeutic targets. For instance, most of the lung adenocarcinomas with EGFR mutations can be treated with EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib. The ALK inhibitor crizotinib has also been proven to improve the progression free survival (PFS) and overall survival (OS) of lung adenocarcinoma patients with ALK rearrangements.

Source: Europe PMC (PubMed Central)

DOI: 10.3978/j.issn.2305-5839.2015.09.10

Authors: Wei Liu, Ting Zhang, Lixia Guo, Yanan Yang

Institutions: Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota), Air Force Medical University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W1803443763

FWCI:

Cites: 14

Cited by:

Related to: 10